ATE397087T1 - Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese - Google Patents

Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese

Info

Publication number
ATE397087T1
ATE397087T1 AT01958342T AT01958342T ATE397087T1 AT E397087 T1 ATE397087 T1 AT E397087T1 AT 01958342 T AT01958342 T AT 01958342T AT 01958342 T AT01958342 T AT 01958342T AT E397087 T1 ATE397087 T1 AT E397087T1
Authority
AT
Austria
Prior art keywords
methods
nucleic acid
pharmaceutical compositions
cells transformed
acid constructs
Prior art date
Application number
AT01958342T
Other languages
English (en)
Inventor
Moshe Flugelman
Zoya Gluzman
Meir Preis
Belly Koren
Tzafra Cohen
Adili Tsaba
Anat Weisz
Original Assignee
Mgvs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mgvs Ltd filed Critical Mgvs Ltd
Application granted granted Critical
Publication of ATE397087T1 publication Critical patent/ATE397087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01958342T 2000-08-08 2001-08-08 Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese ATE397087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22372700P 2000-08-08 2000-08-08

Publications (1)

Publication Number Publication Date
ATE397087T1 true ATE397087T1 (de) 2008-06-15

Family

ID=22837748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01958342T ATE397087T1 (de) 2000-08-08 2001-08-08 Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese

Country Status (13)

Country Link
US (1) US7767201B2 (de)
EP (2) EP1307582B1 (de)
JP (1) JP2004520009A (de)
AT (1) ATE397087T1 (de)
AU (1) AU2001280060A1 (de)
CA (1) CA2418936A1 (de)
CZ (1) CZ2003444A3 (de)
DE (1) DE60134234D1 (de)
HU (1) HUP0300727A3 (de)
IL (1) IL154324A0 (de)
PL (1) PL366000A1 (de)
WO (1) WO2002012539A2 (de)
ZA (1) ZA200301386B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387645B2 (en) * 2003-04-25 2008-06-17 Medtronic Vascular, Inc. Cellular therapy to heal vascular tissue
US20090304650A1 (en) * 2005-05-11 2009-12-10 Scott Edward W Repair of the Bone Marrow Vasculature
EP1948247A4 (de) * 2005-11-15 2010-07-07 Univ Leland Stanford Junior Zusammensetzungen zur koordinierten vegf- und pdgf-expression sowie verwendungsverfahren dafür
JP5121155B2 (ja) * 2006-03-14 2013-01-16 独立行政法人物質・材料研究機構 形質転換細胞集団の作成方法
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
US7943590B2 (en) * 2007-03-16 2011-05-17 Multi-Gene Vascular Systems Ltd. Compositions and methods for treating ophthalmic disorders
CN102242148A (zh) * 2010-10-09 2011-11-16 苏州大学 重组载体以及转基因骨髓基质细胞修饰的丝素膜及其应用
US10383916B2 (en) 2012-11-02 2019-08-20 Cornell University Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium
CN114457003A (zh) * 2020-11-10 2022-05-10 维思尔治疗有限公司 预调节血管细胞用于转导的方法、转导方法和保存转导的细胞的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900556A (en) * 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US6001350A (en) * 1987-12-11 1999-12-14 Somatix Therapy Corp Genetic modification of endothelial cells
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
DK0642585T3 (da) * 1992-05-18 2006-05-15 Genentech Inc Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander
US5618544A (en) * 1992-08-12 1997-04-08 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US6007987A (en) 1993-08-23 1999-12-28 The Trustees Of Boston University Positional sequencing by hybridization
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5821919A (en) * 1994-04-29 1998-10-13 Intel Corporation Apparatus for table-driven conversion of pixels from YVU to RGB format
US6090618A (en) * 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
JP2000502682A (ja) * 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5785965A (en) * 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
IL129474A0 (en) * 1996-10-23 2000-02-29 Univ Wake Forest Targeted cytotoxic cells
FI970784A7 (fi) * 1997-02-25 1998-08-26 Nokia Corp Prosessien välinen vuonvalvonta hajautetussa moniprosessoriympäristössä
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
CA2225185A1 (en) * 1997-08-11 1999-02-11 Peter K. Law Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities
CA2266805C (en) * 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
JP4493854B2 (ja) * 1998-12-23 2010-06-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド リガンドの生物学的活性を増強する方法
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US6554857B1 (en) * 1999-07-20 2003-04-29 Medtronic, Inc Transmural concentric multilayer ingrowth matrix within well-defined porosity
AU2001291019A1 (en) * 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins

Also Published As

Publication number Publication date
ZA200301386B (en) 2004-03-31
PL366000A1 (en) 2005-01-24
US20040151707A1 (en) 2004-08-05
WO2002012539A3 (en) 2002-05-16
HUP0300727A2 (hu) 2003-10-28
IL154324A0 (en) 2003-09-17
EP1307582A2 (de) 2003-05-07
CZ2003444A3 (cs) 2003-10-15
DE60134234D1 (de) 2008-07-10
CA2418936A1 (en) 2002-02-14
EP1307582B1 (de) 2008-05-28
HUP0300727A3 (en) 2005-12-28
JP2004520009A (ja) 2004-07-08
EP1307582A4 (de) 2004-09-22
US7767201B2 (en) 2010-08-03
AU2001280060A1 (en) 2002-02-18
WO2002012539A2 (en) 2002-02-14
EP2163642A1 (de) 2010-03-17

Similar Documents

Publication Publication Date Title
GB0008269D0 (en) Combination chemotherapy
EP1226109A4 (de) Phenylamin-carbonsäure-verbindungen und zubereitungen zur verabreichung von wirkstoffen
FR2822826B1 (fr) Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
DE69725825D1 (de) 5-HT1F-Agonisten
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
NO20073914L (no) Biologisk aktive peptider
ATE397087T1 (de) Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese
MA26802A1 (fr) Derives de streptogramine, leur preparation et les compositions qui les contiennent.
IL174655A0 (en) Drug containing (2r)-2-propyloctanoic acid as the active ingredient
IL135634A0 (en) 5-htif agonists
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
DK1133997T3 (da) Beta-interferon til behandling af immunsygdomme
SE9904404L (sv) Ny komposition
DE60200041D1 (de) Indenoindolon-Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
FR2827287B1 (fr) Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
FR2833955B1 (fr) Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002308369A1 (en) 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties